Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Key facts

Sponsor

Academic and Community Cancer Research United

Principal Investigator

Wen Wee Ma

Academic and Community Cancer Research United

Intervention

Atezolizumab(biological)

Enrollment

122 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2026

Study locations (16)

• Mayo Clinic in Arizona, Scottsdale, Arizona, United States
• Mayo Clinic in Florida, Jacksonville, Florida, United States
• Cleveland Clinic Weston Florida, Weston, Florida, United States
• University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
• Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States
• University Medical Center New Orleans, New Orleans, Louisiana, United States
• Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States
• University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
• Mayo Clinic in Rochester, Rochester, Minnesota, United States
• Roswell Park Cancer Institute, Buffalo, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
• Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
• Rapid City Regional Hospital, Rapid City, South Dakota, United States
• Froedtert and the Medical College of Wisconsin LAPS, Milwaukee, Wisconsin, United States
• +1 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07328009
  A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
  Fudan University
• RECRUITINGNCT07295340
  Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
  West China Hospital
• RECRUITINGPHASE1NCT07364357
  A Phase I Study of CREPT-618 in Locally Advanced HCC
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGPHASE4NCT06717919
  HOPE Against Cancer Recurrence in HCC
  Philipp Dutkowski
• RECRUITINGNCT07173868
  FDG PET-CT in Advanced Breast Cancer
  Samsung Medical Center
• RECRUITINGNANCT06899152
  HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
  Montefiore Medical Center
• RECRUITINGPHASE1, PHASE2NCT07053488
  CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
  AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
• RECRUITINGNANCT06934018
  Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
  Fudan University

See all trials for Pediatric hepatocellular carcinoma →